Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sound-alike, look-alike drug names

Executive Summary

FDA Drug Safety & Risk Assessment Advisory Committee will discuss current screening methods for sound-alike and look-alike proprietary drug names Sept. 19. The meeting will take place at the Holiday Inn in Silver Spring, Md. at 8 a.m. [Editor's note: To sign up for a webcast or video of this meeting, go to FDAAdvisoryCommittee.com]...

You may also be interested in...



Risk management advisory committee plays it safe

FDA postpones Drug Safety & Risk Management Advisory Committee Sept. 18 and 19 meeting as a result of Hurricane Isabel. Committee was slated to discuss labeling and packaging of drug products in low-density polyethylene plastic vials Sept. 18 and screening methods for look-alike, sound-alike proprietary drug names Sept. 19 (1"The Pink Sheet" June 29, 2003, In Brief)...

CES 2020: Panel Discusses Health Care In 2040 – Empowered Consumer, Digital Transformation, Data Sharing, Open Source

An expert panel at CES 2020 discussed Deloitte's vision for health care in 2040, with the empowered consumer managing their own health, enabled by a new ecosystem of secure, open access to data and "nudges" to change behaviors. Consulting firm Deloitte foresees outside disruptors dismantling the traditional health-care system, but panelists from Johnson & Johnson and Anthem flexed their muscles. 

Novartis AveXis President Lennon On Rebuilding Trust With FDA, Zolgensma Trial Hold, And More

AveXis President David Lennon talked to Pink Sheet about quality enhancement at the gene therapy unit, a clinical trial hold for Zolgensma in Type 2 SMA, and expansion in gene therapy.

UsernamePublicRestriction

Register

PS042217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel